Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Companies are deploying siRNA and antisense oligonucleotides to tackle dangerously high cholesterol driven by genetics, betting that a wider population will benefit.
The digitalization of R&D can potentially transform the life sciences, but it cannot succeed without experts collaborating to develop a vision of what a better working environment can look like.
After over a decade of experience with immune checkpoint inhibitors in oncology, more effort needs to be spent unraveling why some patients respond — and why the majority do not — and integrating knowledge about biomarkers into patient selection in trials.
Drug combinations predicted to increase tumor cell death directly and by creating strong antitumor tumor microenvironments were identified by computational analysis of local responses to combinations of anticancer drugs delivered inside a tumor. Such predicted drug combinations were highly effective when administered systemically in mouse models of breast cancer.
Current high-throughput single-cell methods detect only a small part of the transcriptome. The workflow presented here integrates molecular analysis and droplet microfluidics to derive total transcriptomic atlases that encompass alternative splicing and non-coding transcripts in large numbers of single cells. The utility of this method is demonstrated by analysis of mouse gastrulation and early organogenesis.
